Outcomes of patients with limited-stage aggressive large B-cell lymphoma with high-risk cytogenetics

There is a paucity of data regarding outcomes and response to standard therapy in patients with limited-stage (LS) agressive B-cell lymphoma (LS-ABCL) who harbor MYC rearrangement (MYC-R) with or without BCL2 and/or BCL6 rearrangements. We conducted a multicenter retrospective study of MYC-R LS-ABCL...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Blood Adv
Main Authors: Torka, Pallawi, Kothari, Shalin K., Sundaram, Suchitra, Li, Shaoying, Medeiros, L. Jeffrey, Ayers, Emily C., Landsburg, Daniel J., Bond, David A., Maddocks, Kami J., Giri, Anshu, Hess, Brian, Pham, Luu Q., Advani, Ranjana, Liu, Yang, Barta, Stefan Klaus, Vose, Julie M., Churnetski, Michael C., Cohen, Jonathon B., Burkart, Madelyn, Karmali, Reem, Zurko, Joanna, Mehta, Amitkumar, Olszewski, Adam J., Lee, Sarah, Hill, Brian T., Burns, Timothy F., Lansigan, Frederick, Rabinovich, Emma, Peace, David, Groman, Adrienne, Attwood, Kristopher, Hernandez-Ilizaliturri, Francisco J.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2020
Assuntos:
Lymphoid Neoplasia
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6988401/
https://ncbi.nlm.nih.gov/pubmed/31945157
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2019000875
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados